

I. AMENDMENTSIn the claims:

Please amend the claims to read as follows:

1. (Amended) A method of treating rheumatoid arthritis, comprising administering to a mammal in need thereof effective amounts of an anti-CD11a antibody and a TNF- α antagonist.
6. (Twice amended) The method of claim 1, wherein the anti-CD11a antibody is a non T-cell depleting antibody.
7. (Twice amended) The method of claim 1, wherein the TNF- α antagonist is an immunoadhesin.
8. (Amended) The method of claim 7, wherein the immunoadhesin is a fusion of at least a TNF- α binding portion of a TNF- α receptor and an immunoglobulin constant domain sequence.
9. (Amended) The method of claim 8, wherein the immunoadhesin is a TNF- α receptor - IgG Fc fusion protein.
18. (Amended) The method of claim 9, wherein the fusion protein consists of the extracellular ligand binding portion of human tumor necrosis factor receptor linked to the hinge region, CH2 and CH3 domains of human IgG1.
19. (Amended) The method of claim 1 or claim 18, further comprising administering to the mammal an effective amount of ~~methotrexate~~.

Please cancel claims 2, 3, 4, 5 and 17 without prejudice.

Please add the following claims 20 to 25:

20. (New) The method of claim 1 or claim 9, wherein the anti-CD11a antibody is a humanized antibody.
21. (New) The method of claim 1, wherein the TNF- α antagonist is an anti-TNF- α antibody.
22. (New) The method of claim 21, wherein the anti-TNF- α antibody is a chimeric monoclonal antibody.
23. (New) The method of claim 21, wherein the anti-TNF- α antibody is a human or humanized monoclonal antibody.
24. (New) The method of claim 18, wherein the anti-CD11a antibody and fusion protein are administered sequentially.
25. (New) The method of claim 18, wherein the anti-CD11a antibody and fusion protein are administered concurrently.